Overview

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Minocycline
Tigecycline